Company intelligence / Profile preview

Aprica Pharmaceuticals

Paramus, New Jersey, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Aprica Pharmaceuticals was a specialty pharmaceutical company based in Paramus, New Jersey, focused on developing and commercializing products for gastrointestinal disorders. The company's lead product, Pizensy (lactitol), is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults. In May 2016, Aprica was acquired by Sebela Pharmaceuticals, which integrated Aprica's GI portfolio into its own specialized offerings. Pizensy subsequently received FDA approval in February 2020 and is currently marketed by Sebela. The company's strategy involved advancing late-stage clinical assets to address significant unmet needs within the gastroenterology therapeutic area.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Aprica Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aprica Pharmaceuticals.

Explore the full profile